Objective: To conduct a randomized controlled trial to evaluate the effect of a 12-week aerobic exercise program for migraine prevention, plasma cytokines concentrations (TNF-α, interleukin [IL]-1β, IL-6, IL-8, IL-10, and IL-12p70), and anxiety in women with migraine. Methods: Women with episodic migraine (ICHD-II), aged between 20 and 50 years, who had never taken any prophylactic medication, and were physically inactive in the past 12 months were recruited from the university’s hospital and a tertiary headache clinic between March 2012 and March 2015. Migraine attacks were recorded in headache diaries, cytokines were quantified by flow cytometry, and anxiety was assessed by the 7-item General Anxiety Disorder (GAD-7) scale. Blood sampling and psychometric interviews were undertaken on headache-free days. Results: Twenty participants ([mean ± SD] age 33.8 ± 10.5; BMI 26 ± 5.2) were randomly assigned and received intervention (“trained”: n = 10) or entered on a waitlist (“inactive”: n = 10). There were no differences between groups regarding patients’ characteristics and baseline data. Days with migraine (p = 0.001), IL-12p70 levels (p = 0.036), and GAD-7 score (p = 0.034) were significantly reduced in the trained group after the intervention period, but there were no significant changes in these variables in the inactive group. There was no change in the levels of the other cytokines in either group. There were positive correlations between a reduction in IL-12p70 level and a reduction in the number of days with migraine (R2 = 0.19, p = 0.045), and GAD-7 score (R2 = 0.53, p < 0.001). Conclusion: The clinical and psychological therapeutic effects of aerobic exercise in treatment-naïve women with migraine may involve the downregulation of IL-12p70.

Keywords:
Migraine, Chronic pain, Physical activity, Cytokines, Anxiety
1.
Eyre HA, Papps E, Baune BT: Treating depression and depression-like behavior with physical activity: an immune perspective. Front Psychiatry 2013; 4: 1–27.
2.
Pedersen BK: Anti-inflammatory effects of exercise: role in diabetes and cardiovascular disease. Eur J Clin Invest 2017; 47: 600–611.
3.
Walsh NP, Gleeson M, Shephard RJ, Jeffrey MG, Woods A, Bishop NC, et al: Part 1: immune function and exercise. Exerc Immunol Rev 2011; 17: 6–63.
4.
Peake J, Della Gatta P, Suzuki K, Nieman D: Cytokine expression and secretion by skeletal muscle cells: regulatory mechanisms and exercise effects. Exerc Immunol Rev 2015; 21: 8–25.
5.
Mastorakos G, Pavlatou M, Diamanti-Kandarakis E, Chrousos G: Exercise and the stress system. Hormones 2005; 4: 73–89.
6.
Suzuki K, Nakaji S, Kurakake S, Totsuka M, Sato K, Kuriyama T, et al: Exhaustive exercise and type-1/type-2 cytokine balance with special focus on interleukin-12 p40/p70. Exerc Immunol Rev 2003; 9: 48–57.
7.
Varkey E, Cider A, Carlsson J, Linde M: Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia 2011; 31: 1428–1438.
8.
Darabaneanu S, Overath CH, Rubin D, Lüthje S, Sye W, Niederberger U, et al: Aerobic exercise as a therapy option for migraine: a pilot study. Int J Sports Med 2011; 32: 455–460.
9.
Overath CH, Darabaneanu S, Evers MC, Gerber W, Graf M, Keller A, et al: Does an aerobic endurance programme have an influence on information processing in migraineurs ? J Headache Pain 2014; 15: 1–10.
10.
Woldeamanuel Y, Cowan R: The impact of regular lifestyle behavior in migraine: a prevalence case-referent study. J Neurol 2016; 263: 669–676.
11.
Varkey E, Cider A, Carlsson J, Linde M: A study to evaluate the feasibility of an aerobic exercise program in patients with migraine. Headache 2009; 49: 563–570.
12.
GBD 2015 Neurological Disorders Collaborator Group: Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 2017; 11: 877–897.
13.
Vos T, Allen C, Arora M, Barber R, Bhutta Z, Brown A, et al: Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388: 1545–1602.
14.
Mercante J, Peres M, Bernik A: Primary headaches in patients with generalized anxiety disorder. J Headache Pain 2011; 12: 331–338.
15.
Lucchetti G, Peres MFP, Lucchetti ALG, Mercante JPP, Guendler VZ, Zukerman E: Generalized anxiety disorder, subthreshold anxiety and anxiety symptoms in primary headache. Psychiatry Clin Neurosci 2013; 67: 41–49.
16.
Peres M, Mercante J, Tobo P, Kamei H, Bigal M: Anxiety and depression symptoms and migraine: a symptom-based approach research. J Headache Pain 2017; 18: 1–8.
17.
Perini F, D’Andrea G, Galloni E, Pignatelli F, Billo G, Alba S, et al: Plasma cytokine levels in migraineurs and controls. Headache 2005; 45: 926–931.
18.
Bø SH, Davidsen EM, Gulbrandsen P, Diet­richs E, Bovim G, Stovner LJ, et al: Cerebrospinal fluid cytokine levels in migraine, tension-type headache and cervicogenic headache. Cephalalgia 2009; 29: 365–372.
19.
Fidan I, Yüksel S, Ymir T, Irkeç C, Aksakal FN: The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J Neuroimmunol 2006; 171: 184–188.
20.
Duarte H, Teixeira AL, Rocha NP, Domingues RB: Increased interictal serum levels of CXCL8/IL-8 and CCL3/MIP-1a in migraine. Neurol Sci 2014; 36: 203–208.
21.
Sarchielli P, Alberti A, Vaianella L, Pierguidi L, Floridi A, Mazzotta G FA, Gallai V: Chemokine levels in the jugular venous blood of migraine-without-aura patients during attacks. Headache 2004; 44: 961–968.
22.
Boćkowski L, Śmigielska-Kuzia J, Sobaniec W, Zelazowska-Rutkowska B, Wojciech K, Sendrowski K: Anti-inflammatory plasma cytokines in children and adolescents with migraine headaches. Pharmacol Reports 2010; 62: 287–291.
23.
Uzar E, Evliyaoglu O, Yucel Y, Cevik MU, Acar A, Guzel I, et al: Serum cytokine and pro-brain natriuretic peptide (BNP) levels in patients with migraine. Eur Rev Med Pharmacol Sci 2011; 15: 1111–1116.
24.
Oliveira AB, Bachi ALL, Ribeiro RT, Mello MT, Tufik S, Peres MFP: Unbalanced plasma TNF-α and IL-12/IL-10 profile in women with migraine is associated with psychological and physiological outcomes. J Neuroimmunol 2017; 313: 138–144.
25.
Elenkov IJ: Neurohormonal-cytokine interactions: implications for inflammation, common human diseases and well-being. Neurochem Int 2008; 52: 40–51.
26.
Boutron I, Moher D, Altman DG, et al: Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med 2008; 148: 295–309.
27.
Headache Classification Subcommittee of the International Headache Society: The International Classification of Headache Disorders, ed 2. Cephalalgia 2004; 24: 9–160.
28.
Sousa TV, Viveiros V, Chai M V, Vicente FL, Jesus G, Carnot MJ, et al: Reliability and validity of the Portuguese version of the Generalized Anxiety Disorder (GAD-7) scale. Health Qual Life Outcomes 2015; 13: 50.
29.
Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E: Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012; 78: 1337–1345.
30.
Verri WA Jr, Molina RO, Schivo IR, Cunha TM, Parada CA, Poole S, et al: Nociceptive effect of subcutaneously injected interleukin-12 is mediated by endothelin (ET) acting on ETB receptors in rats. J Pharmacol Exp Ther 2005; 315: 609–615.
31.
Goswami S, Samuel S, Sierra OR, Cascardi M, Paré D: A rat model of post-traumatic stress disorder reproduces the hippocampal deficits seen in the human syndrome. Front Behav Neurosci 2012; 6: 1–8.
32.
Elenkov IJ, Kvetnansky R, Hashiramoto A, Bakalov VK, Link A a, Zachman K, et al: Low- versus high-baseline epinephrine output shapes opposite innate cytokine profiles: presence of Lewis- and Fischer-like neurohormonal immune phenotypes in humans? J Immunol 2008; 181: 1737–1745.
33.
Dhabhar FS: Effects of stress on immune function: the good, the bad, and the beautiful. Immunol Res 2014; 58: 193–210.
34.
Elenkov IJ, Chrousos GP: Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. Ann NY Acad Sci 2002; 966: 290–303.
35.
Giraldo E, Garcia JJ, Hinchado MD, Ortega E: Exercise intensity-dependent changes in the inflammatory response in sedentary women: role of neuroendocrine parameters in the neutrophil phagocytic process and the pro-/anti-inflammatory cytokine balance. Neuroimmunomodulation 2009; 16: 237–244.
36.
Steensberg A, Toft AD, Bruunsgaard H, Sandmand M, Halkjaer-Kristensen J, Pedersen BK: Strenuous exercise decreases the percentage of type 1 T cells in the circulation. J Appl Physiol 2001; 91: 1708–1712.
37.
Hoshiyama E, Tatsumoto M, Iwanami H, Saisu A, Watanabe H, Inaba N, et al: Postpartum migraines: a long-term prospective study. Intern Med 2012; 51: 3119–3123.
38.
Sances G, Granella F, Nappi RE, Fignon A, Ghiotto N, Polatti F, et al: Course of migraine during pregnancy and postpartum: a prospective study. Cephalalgia 2003; 23: 5–11.
39.
Borsook D, Maleki N, Becerra L, Mcewen B: Understanding migraine through the lens of maladaptive stress responses: a model disease of allostatic load. Neuron 2012; 73: 219–234.
40.
Leistad RB, Stovner LJ, White LR, et al: Noradrenaline and cortisol changes in response to low-grade cognitive stress differ in migraine and tension-type headache. J Headache Pain 2007; 8: 157–166.
41.
Kuritzky A, Bennet E, Hering R, Ebstein R: Reduced sensitivity of lymphocyte beta-adrenergic receptors in migraine. Headache 1993; 4: 198–200.
42.
Peres MF, Sanchez del Rio M, Seabra ML, Tufik S, Abucham J, Cipolla-Neto J, et al: Hypothalamic involvement in chronic migraine. J Neurol Neurosurg Psychiatry 2001; 71: 747–751.
43.
Woldeamanuel Y, Rapoport A, Cowan R: The place of corticosteroids in migraine attack management: a 65-year systematic review with pooled analysis and critical appraisal. Cephalalgia 2015; 35: 996–1024.
44.
Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A: The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 2009; 8: 40–52.
45.
Chen I, Khan J, Noma N, Hadlaq E, Teich S, Benoliel R, et al: Anti-nociceptive effect of IL-12p40 in a rat model of neuropathic pain. Cytokine 2013; 62: 401–406.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.